文献速递淋巴瘤造血干细胞移植与细胞治疗

60岁及以下原发性中枢神经系统淋巴瘤患者的放疗或自体干细胞移植:随机II期PRECIS研究的长期结果

Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study.
PubMed 文献 · J Clin Oncol · 2022-07-14

PRECIS研究为随机II期试验,初诊原发性中枢神经系统淋巴瘤患者(18-60岁)接受大剂量甲氨蝶呤为基础的诱导化疗后,分别接受全脑放疗(WBRT)或大剂量化疗联合自体干细胞移植(ASCT)。中位随访8年的长期数据显示,ASCT组8年无事件生存率为67%,WBRT组为39%(P=0.03),ASCT组复发风险显著更低(HR=0.13,P<0.001);WBRT组平衡功能和神经认知功能显著恶化。作者认为40 Gy WBRT因神经毒性和降低复发效果欠佳应避免用于一线治疗,而ASCT在预防复发方面似乎高效。

要点

  • ASCT组8年无事件生存率67% vs WBRT组39%(P=0.03),ASCT组复发风险显著更低(HR=0.13,P<0.001)。
  • 8年总生存率ASCT组69% vs WBRT组65%,无显著差异。
  • WBRT组平衡功能(52% vs 10%,P≤0.001)和神经认知功能(64% vs 13%,P<0.001)显著恶化。

核心结论

  • 作者认为40 Gy WBRT因神经毒性和降低复发效果欠佳应避免用于一线治疗,而ASCT在预防复发方面似乎高效。

研究设计与样本

  • 随机II期PRECIS研究,纳入初诊原发性中枢神经系统淋巴瘤患者(18-60岁),接受大剂量甲氨蝶呤为基础的诱导化疗后随机接受WBRT或大剂量化疗(塞替派-白消安-环磷酰胺)联合ASCT。
  • WBRT组53例,ASCT组44例;本次报告中位随访8年。

主要发现

  • 8年无事件生存率ASCT组67% vs WBRT组39%(P=0.03),ASCT组复发风险显著更低(HR=0.13,P<0.001)。
  • WBRT组复发后经挽救治疗,三分之一患者存活。
  • ASCT组5例、WBRT组4例分别死于治疗相关毒性。
  • 8年总生存率ASCT组69% vs WBRT组65%,无显著差异。
  • 随访期间WBRT组较ASCT组平衡功能(52% vs 10%,P≤0.001)和神经认知功能(64% vs 13%,P<0.001)显著恶化。

临床怎么用

  • 作者认为40 Gy WBRT因神经毒性和降低复发效果欠佳应避免用于一线治疗,而ASCT在预防复发方面似乎高效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.We previously reported the results of a randomized phase II study in patients with newly diagnosed primary CNS lymphoma (age 18-60 years). Patients were treated with high-dose methotrexate-based induction chemotherapy followed by whole-brain radiotherapy (WBRT) or high-dose chemotherapy (thiotepa-busulfan-cyclophosphamide) with autologous stem-cell transplantation (ASCT). The median follow-up was 33 months. In this report, we provide long-term data (median follow-up, 8 years) regarding the outcomes and toxicities. Fifty-three and 44 patients received induction chemotherapy followed by WBRT or ASCT, respectively. Their 8-year event-free survival from random assignment was 67% and 39% in the ASCT and WBRT arms, respectively (P = .03), with a significantly lower risk of relapse after ASCT (hazard ratio, 0.13; P < .001). One third of patients who relapsed after WBRT were alive after salvage treatment. Five and four patients died of ASCT and WBRT-related toxicities, respectively. The 8-year overall survival was 69% and 65% in the ASCT and WBRT arms, respectively (not significant). Balance (52% v 10%, P ≤ 0.001) and neurocognition (64% v 13%, P < .001) significantly deteriorated after WBRT compared with ASCT during the follow-up. This study shows that 40 Gy WBRT should be avoided in first-line treatment because of its neurotoxicity and suboptimal efficacy in reducing relapses while ASCT appears to be highly efficient in preventing relapses.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Houillier C, Dureau S, Taillandier L, et al. Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study. J Clin Oncol. 2022. PMID: 35834762. doi:10.1200/JCO.22.00491

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。